Show simple item record

dc.contributor.authorSchlegel, J.
dc.contributor.authorHoffmann, J.
dc.contributor.authorRoll, D.
dc.contributor.authorMuller, B.
dc.contributor.authorGunther, S.
dc.contributor.authorZhang, Wei
dc.contributor.authorJanise, A.
dc.contributor.authorVossing, C.
dc.contributor.authorFuhler, B.
dc.contributor.authorNeidhardt, J.
dc.contributor.authorKhanna, Hemant
dc.contributor.authorLorenz, B.
dc.contributor.authorStieger, K.
dc.date2022-08-11T08:09:52.000
dc.date.accessioned2022-08-23T16:46:40Z
dc.date.available2022-08-23T16:46:40Z
dc.date.issued2019-01-01
dc.date.submitted2019-02-28
dc.identifier.citation<p>Transl Res. 2019 Jan;203:57-72. doi: 10.1016/j.trsl.2018.08.006. Epub 2018 Aug 24. <a href="https://doi.org/10.1016/j.trsl.2018.08.006">Link to article on publisher's site</a></p>
dc.identifier.issn1878-1810 (Linking)
dc.identifier.doi10.1016/j.trsl.2018.08.006
dc.identifier.pmid30213530
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40925
dc.description.abstractGenome editing represents a powerful tool to treat inherited disorders. Highly specific endonucleases induce a DNA double strand break near the mutant site, which is subsequently repaired by cellular DNA repair mechanisms that involve the presence of a wild type template DNA. In vivo applications of this strategy are still rare, in part due to the absence of appropriate animal models carrying human disease mutations and knowledge of the efficient targeting of endonucleases. Here we report the generation and characterization of a new mouse model for X-linked retinitis pigmentosa (XLRP) carrying a point mutation in the mutational hotspot exon ORF15 of the RPGR gene as well as a recognition site for the homing endonuclease I-SceI. Presence of the genomic modifications was verified at the RNA and protein levels. The mutant protein was observed at low levels. Optical coherence tomography studies revealed a slowly progressive retinal degeneration with photoreceptor loss starting at 9 months of age, paralleling the onset of functional deficits as seen in the electroretinogram. Early changes to the outer retinal bands can be used as biomarker during treatment applications. We further show for the first time efficient targeting using the I-SceI enzyme at the genomic locus in a proof of concept in photoreceptors following adeno-associated virus mediated gene transfer in vivo. Taken together, our studies not only provide a human-XLRP disease model but also act as a platform to design genome editing technology for retinal degenerative diseases using the currently available endonucleases.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=30213530&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectgenome editing
dc.subjectretina
dc.subjectneurons
dc.subjectmouse model
dc.subjectendonucleases
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectCongenital, Hereditary, and Neonatal Diseases and Abnormalities
dc.subjectEnzymes and Coenzymes
dc.subjectEye Diseases
dc.subjectGenetics and Genomics
dc.subjectMolecular and Cellular Neuroscience
dc.subjectNucleic Acids, Nucleotides, and Nucleosides
dc.subjectOphthalmology
dc.subjectTranslational Medical Research
dc.titleToward genome editing in X-linked RP-development of a mouse model with specific treatment relevant features
dc.typeJournal Article
dc.source.journaltitleTranslational research : the journal of laboratory and clinical medicine
dc.source.volume203
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4736&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3724
dc.identifier.contextkey13921332
refterms.dateFOA2022-08-23T16:46:40Z
html.description.abstract<p>Genome editing represents a powerful tool to treat inherited disorders. Highly specific endonucleases induce a DNA double strand break near the mutant site, which is subsequently repaired by cellular DNA repair mechanisms that involve the presence of a wild type template DNA. In vivo applications of this strategy are still rare, in part due to the absence of appropriate animal models carrying human disease mutations and knowledge of the efficient targeting of endonucleases. Here we report the generation and characterization of a new mouse model for X-linked retinitis pigmentosa (XLRP) carrying a point mutation in the mutational hotspot exon ORF15 of the RPGR gene as well as a recognition site for the homing endonuclease I-SceI. Presence of the genomic modifications was verified at the RNA and protein levels. The mutant protein was observed at low levels. Optical coherence tomography studies revealed a slowly progressive retinal degeneration with photoreceptor loss starting at 9 months of age, paralleling the onset of functional deficits as seen in the electroretinogram. Early changes to the outer retinal bands can be used as biomarker during treatment applications. We further show for the first time efficient targeting using the I-SceI enzyme at the genomic locus in a proof of concept in photoreceptors following adeno-associated virus mediated gene transfer in vivo. Taken together, our studies not only provide a human-XLRP disease model but also act as a platform to design genome editing technology for retinal degenerative diseases using the currently available endonucleases.</p>
dc.identifier.submissionpathoapubs/3724
dc.contributor.departmentDepartment of Ophthalmology
dc.source.pages57-72


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1_s2.0_S1931524418301415_main.pdf
Size:
4.598Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as Copyright 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).